[PDF] Top 20 Propuesta de un modelo de inclusión laboral para personas con discapacidad
Has 10000 "Propuesta de un modelo de inclusión laboral para personas con discapacidad" found on our website. Below are the top 20 most common "Propuesta de un modelo de inclusión laboral para personas con discapacidad".
Update on the development of lurasidone as a treatment for patients with acute schizophrenia
... study, lurasidone administered once- daily in the evening at 80 mg and 160 mg demonstrated supe- riority compared to placebo in terms of PANSS total ...visits. Lurasidone was well-tolerated, displaying no ... See full document
5
Clinical potential of lurasidone in the management of schizophrenia
... antipsychotics. Lurasidone has demonstrated its efficacy in several short-term trials in acute schizophrenia, promptly and significantly reducing total Positive and Negative Syndrome Scale and Brief ... See full document
9
A PROSPECTIVE STUDY ON THE TREATMENT FOR ACUTE ISCHEMIC STROKE & AN UPDATE OF CURRENT TREND FOR THE MANAGEMENT OF BLOOD PRESSURE IN PATIENTS WITH AIS IN A TERTIARY CAE HOSPITAL, BANGALORE
... Due to the thrombotic origin of AIS and the involvement of platelet aggregation in the development of said thrombus, anti-platelet drugs play an obvious and pivotal role in the Neurodegenerative Diseases medical ... See full document
11
Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients
... of patients were on quetiapine at the time of recovery from catatonia and ...of patients were on quetiapine at the time of discharge as compared to only ...of patients on quetiapine on ...29 ... See full document
19
An update on PARP inhibitors for the treatment of cancer
... The development of poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation–related ... See full document
5
A Randomized, Prospective Comparative Study to Evaluate the Efficacy and Safety of Lurasidone and Risperidone in Treatment of Schizophrenia
... EPS at clinically effective doses, including parkinsonism (muscle rigidity, tremor, bradykinesia), acute dystonic reactions, dyskinesias, akathisia and tardive dyskinesia. They are also called neuroleptics because ... See full document
101
Schizophrenia relapse, patient considerations, and potential role of lurasidone
... ill patients received 12–24 weeks of treatment with lurasidone at a starting dose of 40 mg/d, with flexible dosing permitted after 3 days up until the last 4 weeks of the stabilization period, during ... See full document
6
On the decision rules of cost-effective treatment for patients with diabetic foot syndrome
... alternative treatment interventions in patients with diabetic foot ...effective treatment. Finally, our study reveals that treatment programs are highly cost-effective for patients at ... See full document
5
Evaluation of the Oral Sildenafil Effect on the Recovery of Patients with Acute Ischemic Stroke
... the treatment of stroke and subarachnoid hemorrhage and dementia and learning, and neurodegenerative disorder ...medullar patients for years It is certain that as the desired effects of this drug, t also ... See full document
257
An update on mindfulness meditation as a self-help treatment for anxiety and depression
... the treatment of symptoms of anxiety and depression in both clinical and nonclinical ...independent treatment approaches for both the symptoms of anxiety and depression, as well as anxiety and depressive ... See full document
5
Development of a Barthel Index based on dyspnea for patients with respiratory diseases
... consecutive patients (Phase 2) were ...follows: patients with any CRD (mainly COPD, emphysema, and chest wall diseases) admitted to any of three rehabilitation wards and with arterial blood gases (ABG) sta- ... See full document
8
Revisiting loxapine: a systematic review
... in schizophrenia and mania. Acute agitation, characterized by motor restlessness and mental tension, is a serious medical problem that may be present in various psychiatric disorders, including ... See full document
17
An update on belimumab for the treatment of lupus
... belimumab-treated patients was maintained or increased to 10 ...of patients dropped out during the placebo-controlled portion of the study, whereas 296 were enrolled at week 80 in the open-label, ... See full document
85
Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder
... Results: Asenapine was found to be efficacious for manic and mixed states in bipolar disorder compared with placebo control, and compares equally well to olanzapine on efficacy measures after 3 weeks of treatment. ... See full document
8
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
... first-line treatment of patients without 17p ...with treatment- related mortality exceeding ...fit patients, there is no OS benefit and the PFS and ORR advantage is not maintained for ... See full document
16
<p>Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib</p>
... for patients with relapsed/refractory SqCC of the lung, only afatinib, an irreversible ErbB family blocker, has data of Chinese ...that patients with ErbB mutations, especially ErbB2, and those classified ... See full document
16
In-hospital stroke
... This special vulnerability may be the consequence of a general prothrombotic state due to inflammatory reactions and reduced organ function in critically ill patients or of necessary withdrawal of anticoagulation. ... See full document
7
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
... the treatment of metastatic RCC undergoing the most radical ...the development of a new treatment ...of patients with metastatic RCC utilize knowledge of histology, molecular abnormalities, ... See full document
68
<p>Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective</p>
... Elotuzumab (Elo) is a humanized IgG1 mAb directed against SLAMF7, also called CS1 (cell surface glycoprotein CD2 subset 1). 12,13 SLAMF7 is a glycoprotein highly expressed on most normal and abnormal plasma cells, and ... See full document
9
Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice
... in treatment of acute and chronic toxoplasmosis in mouse ...in treatment of acute and chronic toxoplasmosis in ...in acute and chronic ...the treatment of acute and ... See full document
6
Related subjects